Meca-Lallana, J-E; Fernández-Prada, M; García-Vázquez, E; Moreno-Guillén, S; Otero-Romero, S; Rus-Hidalgo, M; Villar-Guimerans, L-M; Eichau-Madueno, S; Fernández-Fernández, O; Izquierdo-Ayuso, G; Álvarez-Cermeno, José-C; Arnal-García, C; Arroyo-González, R; Brieva-Ruiz, L; Calles-Hernández, C; García-Merino, A; González-Platas, M; Hernández-Pérez, M-A; Moral-Torres, E; Olascoaga-Urtaza, J; Oliva-Nacarino, P; Oreja-Guevara, C; Ortiz-Castillo, R; Oterino, A; Prieto-González, J-M; Ramio-Torrenta, L; Rodríguez-Antiguedad, A; Saiz, A; Tintore, M; Montalban-Gairin, X
(ELSEVIER ESPANA SLU, 2022-10)
INTRODUCTION: Alemtuzumab is a highly effective drug approved by the European Medicines Agency as a disease-modifying drug for the treatment of relapsing-remitting multiple sclerosis. OBJECTIVE: A consensus document was ...